Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698733 | 0.83 | LMNA (0.58) | ARSMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL4469579 | 0.79 | SMN1; SMN2 (0.53) | ARSMN1; SMN2TP53HSD17B10ALOX15 | |
| SCHEMBL3511935 | 0.77 | L3MBTL1 (0.54) | ARSMN1; SMN2TP53HSD17B10ALOX15 | |
| SCHEMBL18674672 | 0.73 | AR (0.54) | ARSMN1; SMN2TP53HSD17B10ALOX15 | |
| SCHEMBL17266285 | 0.73 | AR (0.54) | ARSMN1; SMN2TP53HSD17B10ALOX15 | |
| SCHEMBL22334869 | 0.73 | AR (0.54) | ARSMN1; SMN2TP53HSD17B10ALOX15 | |
| SCHEMBL18674673 | 0.73 | AR (0.54) | ARSMN1; SMN2TP53HSD17B10ALOX15 | |
| SCHEMBL4472290 | 0.73 | L3MBTL1 (0.54) | ARSMN1; SMN2TP53HSD17B10ALOX15 | |
| SCHEMBL2624023 | 0.72 | RAB9A (0.58) | ARSMN1; SMN2TP53HSD17B10ALOX15 | |
| SCHEMBL28910899 | 0.72 | SMN1; SMN2 (0.53) | ARSMN1; SMN2TP53HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173137-B2 | Epothilone analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040127432-A1 | Epothilone analogs | THE SCRIPPS RESEARCH INSTITUTE | 2004-07-01 | — | — | US | disclosed |
| US-6660758-B1 | Prevention of mitosis; induction and stabilization of microtubules | THE SCRIPPS RESEARCH INSTITUTE | 2003-12-09 | — | — | US | disclosed |
| US-6441186-B1 | ANTICANCER AGENTS; PREVENTION OF MITOSIS THROUGH INDUCTION AND STABILIZATION OF MICROTUBULIN ASSEMBLY; SUPERIOR CYTOTOXIC ACTIVITIES | THE SCRIPPS RESEARCH INSTITUTE | 2002-08-27 | — | — | US | disclosed |
| EP-0944634-A1 | EPOTHILONE ANALOGS | Novartis AG (CH) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025929-A1 | EPOTHILONE ANALOGS | NOVARTIS AG (CH) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127432-A1 | Epothilone analogs | TUBB8B, TUBB1, TUBA1B | AR 2992/4885SMN1; SMN2 1659/4885TP53 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.